Some interesting news for those struggling with dry eye disease: Two new investigational therapies aim to treat the root causes of the disease rather than just managing the symptoms. Traditionally, dry eye has been treated with anti-inflammatory eye drops. However, experts now believe that focusing on the underlying issues, such as tear film imbalance and meibomian gland dysfunction (MGD), might be more effective.
Selenium Sulfide Cream for MGD
One of the therapies in development, AZR-MD-001 by Azura Ophthalmics, is a selenium sulfide ointment applied to the eyelids. It's designed to address meibomian gland dysfunction, a common cause of tear film imbalance. In phase 2 trials, this cream helped improve the number and quality of active oil-producing glands in the eyelids. This could mean better lubrication and fewer dry eye symptoms for you. It's not on the market yet, as they are still awaiting approval from the FDA.
Vezocolmitide for Epithelial Repair
The second therapy, vezocolmitide or ST-100 by Stuart Therapeutics, targets damage to the eye's surface. It's a collagen mimetic peptide that repairs damaged collagen in the eye, promoting healing and stability in the cornea. In clinical trials, significant improvements were seen quickly, even within days. This therapy might be particularly useful for those with early-stage neurotrophic keratitis, a condition where part of the eye's surface is damaged but not painful. Phase 3 trials are underway to confirm how well it works and if it’s safe for longer use.
These developments highlight a shift towards personalized treatment for dry eye, focusing on what's really causing the issue rather than just its symptoms. Although these treatments are not yet available, they offer hope for more effective management in the near future. Always check with your eye doctor about new treatment options.
Source: Ophthalmology Times